Highlights

  • FY26 Revenue increased to $2.10 million following the launch of the US remote patient monitoring program.
  • Hailie® platform supports remote monitoring of medication usage and respiratory adherence data.
  • Adherium ended FY26 with cash of $1.42 million.
  • Trudell Medical provided a consolidated A$4.67 million unsecured term Loan Facility for Working Capital requirements.

Adherium Limited (ASX:ADR) is a digital health company focused on connected respiratory medical devices and remote patient monitoring solutions. The company developed the US FDA-cleared Hailie® Smartinhaler® platform, which enables clinicians, healthcare providers and patients to monitor respiratory medication usage and adherence. During FY26, Adherium transitioned from a clinical trials-focused company toward a data-driven remote patient monitoring Business model.

Hailie® Platform Drives Commercial Transition

Adherium reported progress in commercialising its Hailie® Smartinhaler® platform during FY26. The company launched its remote patient monitoring program in the United States, contributing to revenue growth during the period.

Revenue for FY26 was $2.10 million compared with $817,237 in FY25, representing an increase of 157%. The company attributed growth to the successful launch of the US remote patient monitoring program.

Adherium’s Hailie® solution provides digital monitoring capabilities by capturing medication usage parameters and adherence information through connected sensors, mobile applications and software integration tools.

The company stated that it has transitioned from a Clinical Trials company to a data-driven remote patient monitoring company, providing adherence and technique monitoring services through monthly subscription arrangements.

Investment in Commercial Growth and Platform Development

During FY26, Adherium invested in commercial infrastructure to support expansion in the US market. The company expanded engineering capability, invested in quality assurance functions and increased sales and customer support resources.

Research and development expenditure for FY26 was $2.08 million compared with $3.44 million in FY25, reflecting a shift from clinical trials and product development toward commercialisation activities.

Sales and Marketing costs were $1.80 million during FY26 compared with $4.29 million in the previous year.

Administrative expenses increased to $11.70 million, primarily due to higher payroll, contractor and consulting costs, capital raising expenses and executive recruitment activities.

Funding Support and Future Respiratory Care Strategy

Adherium ended FY26 with cash of $1.42 million compared with $43,255 in FY25. The company also secured additional funding support from major Shareholder Trudell Medical Limited.

The funding arrangements were consolidated into a term loan facility of A$4.67 million due on 31 August 2027. The unsecured facility carries interest at 12% per annum and is intended to support working capital requirements.

Adherium continues focusing on expanding Hailie® adoption, growing remote patient monitoring subscriptions and supporting healthcare providers with digital respiratory management tools.

The company’s platform includes sensors connected to respiratory medications, software development tools and API integration capabilities designed to enable healthcare data capture and sharing.

Key Insights

Adherium is progressing its digital respiratory healthcare strategy through the commercial rollout of the Hailie® platform and US remote patient monitoring program. FY26 marked a transition toward subscription-based monitoring services supported by additional funding and platform development.